AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
- Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
- or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
- If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
- Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.